BioPharma Dive

Sept. 19, 2023

Read the full release >>

BOSTON–(BUSINESS WIRE)–OM1, a leading real-world data, AI and technology company with a focus on chronic diseases, today announced the appointment of Shawn Bates as Chief Commercial Officer. Bates will work cross-functionally to steer OM1’s commercial strategy – including sales, marketing, and commercial operations – widening the company’s reach across the healthcare and life sciences industries. His efforts will further OM1’s goal to provide deeply rooted, high quality, real-world data and evidence to accelerate research, drive new treatment insights and improve clinical decision making.

“Not only is Shawn joining us with a reputation of incredible global transformational leadership, but his passion for enabling and accelerating innovation that offers hope to patients with difficult-to-treat diseases is deeply aligned with our mission at OM1,” said Dr. Richard Gliklich, Founder and CEO, OM1. “I believe that with his product development and commercialization experience he will greatly accelerate our commercial momentum by expanding the reach of our solutions and our ability to positively impact the healthcare ecosystem.”

Bates brings nearly 30 years of leadership and life sciences expertise to OM1, most recently serving as the Global Commercial Head for Certara’s RWE, Access, MedAffairs, and Regulatory business unit. Prior to that, he served as the General Manager for Certara’s Evidence, Access, and MedAffairs software portfolio. In these roles, Bates championed and scaled customer-centric commercial frameworks, yielded successive years of robust growth, and unveiled a fresh go-to-market approach that saw the expansion and launch of new services.

“The healthcare industry is at an exciting and pivotal moment as leaders across the ecosystem integrate advanced technology, AI and machine learning throughout business operations to advance how therapies and treatments are delivered to patients,” said Shawn Bates, Chief Commercial Officer, OM1. “OM1 is at the forefront, reshaping how treatments are developed and clinical decisions are made with its real-world data and artificial intelligence solutions, and I am thrilled to have the opportunity to contribute to this change-making team.”

To learn more about the OM1’s real-world data, evidence generation, and AI & predictive medicine solutions, please email

About OM1

With specialization in chronic conditions, OM1 is re-imagining real-world evidence and insights by developing large electronically connected networks of clinicians and health data in dermatology, rheumatology, gastroenterology, cardiology, metabolism, respiratory, mental health, neurology and other specialty areas. Leveraging its data automation platform, OM1 Aspen, extensive clinical networks and artificial intelligence (AI) platform, PhenOM™, OM1 offers industry-leading enriched healthcare datasets, retrospective and prospective studies, advanced analytics, and AI-driven guidelines adherence and decision-support around diagnosis, risk management, and treatment. With a focus on high-quality data and clinical outcomes, the offerings are used for accelerating research, demonstrating treatment effectiveness, supporting regulatory submissions, monitoring safety, and informing commercialization.


Alyssa Horowitz